3results about How to "Lower triglyceride levels" patented technology

The invention belongs to the field of pharmaceutical preparations. The invention relates to lipid nanoparticles modified by probiotic coupled galactose and coated with diammonium glycyrrhizinate, L-arginine and copper tannic acid nano enzyme as well as a preparation method and application of the lipid nanoparticles. The lipid nanoparticles prepared by coupling and wrapping the diammonium glycyrrhizinate, the L-arginine and the copper tannic acid nano-enzyme with the probiotics have good biocompatibility, the preparation method is simple, the particle size distribution of the nanoparticles is uniform, the half-life period of a medicine circulating in a body can be prolonged, the inherent beneficial functions of the probiotics are cooperated, and the bioavailability of the medicine is improved. The potential application value is realized in the fields of treating the metabolic dysfunction related steatohepatitis and the like.

This invention discloses a strain of *Lactobacillus plantarum* CCFM1487 and its prepared metagener for lowering lipids and alleviating fatty liver, as well as its application in converting cassiaside. It belongs to the fields of microbial technology and food and health product technology. This strain can efficiently convert cassiaside into cassiaside aglycone. The core of this invention lies in providing a metagener prepared from this strain through fermentation and inactivation treatment. Experiments in a high-fat diet mouse model have demonstrated that it significantly reduces serum total cholesterol and triglyceride levels, and can alleviate hepatic lipid deposition and improve hepatic steatosis. Based on this metagener, foods, medicines, or health products can be developed for the prevention and / or adjuvant treatment of metabolic disorders such as hyperlipidemia and non-alcoholic fatty liver disease, possessing significant application value.

The application provides use of a specific KPNA2 agonist and a combination of the specific KPNA2 agonist and other substances in preparation of a product for preventing or treating fatty liver. It is found for the first time that the specific KPNA2 agonist can significantly reduce liver triglyceride levels, thereby reducing alcohol-induced liver steatosis, and has good clinical conversion prospects, and the combination of the specific KPNA2 agonist and other substances has better effects.